Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.

Abstract

Limited evidence is available on the utility of dose-escalated radiation therapy (DE-RT) with or without temozolomide (TMZ) versus standard-of-care radiation therapy (SoC-RT) for patients with newly diagnosed glioblastoma multiforme. We performed a systematic review/meta-analysis to compare overall survival (OS) and progression-free survival (PFS) between DE-RT and SoC-RT. We used a Population, Intervention, Control, Outcomes, Study Design/Preferred Reporting Items for Systematic Reviews and Meta-analyses/Meta-analysis of Observational Studies in Epidemiology selection criterion to identify studies. The primary and secondary outcomes were 1-year OS and 1-year PFS, respectively. Outcomes and comparisons were subdivided based on receipt of TMZ and MGMT status. DE-RT was defined based on equivalent dose calculations. Random effects meta-analyses using the Knapp-Hartung correction, arcsine transformation, and restricted maximum likelihood method were conducted. Meta-regression was used to compare therapeutic (eg, DE-RT or TMZ) and pathologic characteristics (eg, MGMT methylation status) using the Wald-type test. Across 22 published studies, 2198 patients with glioblastoma multiforme were included; 507 received DE-RT. One-year OS after DE-RT alone was higher than SoC-RT alone (46.3% vs 23.4%; P=.02) as was 1-year PFS (17.9% vs 5.3%; P=.02). No significant difference in 1-year OS (73.2% vs 64.4%; P=.23) or 1-year PFS (44.5% vs 44.3%; P=.33) between DE-RT+TMZ and SoC-RT+TMZ was noted. No difference in 1-year OS was noted between DE-RT+TMZ and SoC-RT+TMZ in either MGMT methylated (83.2% vs 73.2%; P=.23) or MGMT unmethylated (72.6% vs 50.6%; P=.16) patients. DE-RT alone resulted in superior PFS and OS versus SoC-RT alone. DE-RT+TMZ did not lead to improved outcomes versus SoC-RT+TMZ. No differential benefit based on MGMT status was found. Future studies are warranted to define which subgroups benefit most from DE-RT.